Neurorehabilitation Devices Companies

Why Neurorehabilitation Devices Market Is Expanding?

The Global Neurorehabilitation Devices Market reached an estimated USD 1,890 million in 2025 and is projected to grow from USD 2,170 million in 2026 to approximately USD 6,980 million by 2035, registering a CAGR of 14.8% over the forecast period (2026–2035). This acceleration is anchored to two converging forces: the global surge in neurological disorder prevalence — with over 1 billion people worldwide suffering from neurological disorders and over 55 million now living with dementia alone — and aggressive government investment in brain injury recovery tools through programs like the U.S. BRAIN Initiative, which has channeled more than USD 3.2 billion into neuroscience research since inception.

A transformative technology shift is altering the scene. Robotic-assisted neuro treatment platforms, closed-loop brain-computer interfaces, and AI-driven cognitive rehabilitation technology are replacing legacy manual therapy regimens and passive rehabilitation equipment. The IpsiHand System, a brain-computer interface for stroke rehabilitation, received De Novo authorization from the FDA in April 2021, marking a regulatory turning point, and investment in neural plasticity therapy devices has since topped USD 780 million annually through venture and strategic channels. Hospital systems are already replacing static exercise stations with sensor-equipped neuro-robotic devices that record real-time data on the patients’ neuroplasticity.

What Structurally Separates Leaders from the Field?

MRFR identifies four structural factors that define category leadership in the Neurorehabilitation Devices Market: proprietary robotic kinematics and motion-control algorithms that deliver quantifiable, repeatable therapy outcomes superior to conventional rehabilitation; regulatory portfolio breadth spanning FDA 510(k), De Novo, CE Mark, and NMPA clearances that create multi-market revenue streams; integrated software-hardware platforms that generate longitudinal patient data, enabling outcome-based payment models and recurring subscription revenue; and strategic partnerships with academic medical centers and national health systems that create installed-base lock-in and clinical evidence moats. Companies that combine at least three of these four factors — Hocoma (DIH Group), Medtronic, and Ekso Bionics among them — command disproportionate pricing power and hospital formulary preference.

Top 10 Global Neurorehabilitation Devices Companies — MRFR Rankings (2026)

MRFR has identified and profiled the following leading neurorehabilitation devices companies globally, evaluated on the basis of revenue performance, geographic presence, product breadth, technology strategy, innovation investment, and regulatory portfolio. Figures below have been validated against company filings, investor-relations disclosures, and official company websites as of July 2026.

Detailed Company Profiles

1. Medtronic plc | NYSE: MDT | Dublin, Ireland

Medtronic participates in the neurorehabilitation devices market through its Neuromodulation division, which generated USD 1,932 million in FY2025 revenue — an 11% year-over-year increase supported by higher demand for pain and movement disorder therapies. The company's Neuroscience Portfolio overall delivered USD 9,846 million in FY2025.

Medtronic’s competitive advantage in neurorehabilitation is based on its closed-loop neurostimulation architecture: the Percept™ RC neurostimulator with BrainSense™ technology, launched in FY2024, captures real-time brain signal data to automatically adjust stimulation parameters, a capability that no other competitor has at commercial scale. Its Inceptiv™ closed-loop spinal cord stimulator was approved by the FDA in April 2024, bringing this adaptive stimulation platform to pain management. Medtronic has an installed base of DBS and SCS systems in over 150 countries, providing ongoing income streams from battery replacements, programming services and software upgrades, which smaller neuro-robotic competitors that offer one-time capital equipment can’t match. Medtronic’s $2.84 billion annual R&D budget (FY2024) drives a pipeline of optogenetic stimulation and customized neurochemical delivery, positioning Medtronic to catch the next wave of discoveries in neural plasticity.

2. Abbott Laboratories | NYSE: ABT | Abbott Park, Illinois, USA

Abbott Laboratories is also active in neurorehabilitation through its Neuromodulation business in the Medical Devices segment. Neuromodulation generated sales of USD 962 million in FY2024, up from USD 890 million in FY2023, representing double-digit growth. In FY2024, Abbott’s overall company net sales were USD 41.95 billion, with its Medical Devices division recording USD 18.99 billion and a 32.4% operating margin. Abbott’s strategic positioning in neurorehabilitation is driven by cross-divisional synergies. Neuromodulation can leverage Abbott’s dominant hospital relationships by sharing a common digital platform and sales infrastructure with the cardiovascular, diabetes care, and neuromodulation divisions. The company’s annual R&D investment of USD 2.84 billion supports a neuromodulation pipeline that includes next-generation DBS, SCS and BCI research.

3. Hocoma (DIH Technologies) | NASDAQ: DHAI | Volketswil, Switzerland

Hocoma is the neuro-robotic rehabilitation trademark of DIH Technologies, a NASDAQ-listed business (NASDAQ: DHAI) founded in Beijing, China, with headquarters in Volketswil, Switzerland. DIH’s total revenue in FY2025 (year ended March 31, 2025) was USD 62.9 million, down marginally from USD 64.5 million in FY2024. The drop was mostly due to changes in product mix and geographic demand. Hocoma’s product portfolio is the most comprehensive neuro-robotic rehabilitation platform in the world, with systems such as Lokomat (robotic gait training), Armeo (upper-extremity rehabilitation), Erigo (early mobilization), C-Mill (treadmill with VR) and CAREN/Grail (virtual reality balance training) installed in more than 4,500 hospitals in EMEA, the Americas and Asia-Pacific. Hocoma’s competitive differentiation is its end-to-end rehabilitation ecosystem. No competitor has simultaneous lower-extremity, upper-extremity, balance, and early-mobilization robotic systems from a single vendor, creating bundling advantages for procurement and reducing hospital integration costs. The company’s 178-person staff has strong clinical ties with rehab institutions and academic hospitals that create real-world evidence to justify payer reimbursement.

4. Ekso Bionics Holdings, Inc. | NASDAQ: EKSO | San Rafael, California, USA

Ekso Bionics, a publicly traded developer of lower-extremity exoskeleton devices for medical and industrial rehabilitation, is based in San Rafael, California. The company reported total revenue of ~USD 12.8 million in FY2025 (SEC 10-K filed February 2026), down from USD 17.9 million in FY2024. Q3 2025 revenue was USD 4.2 million, an increase of 2% compared to Q3 2024. Ekso Bionics’ FY2025 path forward was powered by strategic distribution growth, as the company announced the appointment of National Seating & Mobility (180+ locations) and Bionic Prosthetics & Orthotics Group (12 states) as exclusive distributors of its Ekso Indego® Personal device, a lightweight powered exoskeleton for people with spinal cord injury and stroke. Ekso Bionics cut operating cash burn by 43% in Q1 2025 over the prior year, expanding its cash runway. As of September 30, 2025, the company has cash of $2.7 million and is nonetheless capital-constrained relative to larger competitors.

5. Bionik Laboratories Corp. | TSE: BNKL | Toronto, Ontario, Canada

Bionik Laboratories is a Toronto, Canada-based public healthcare robotics business developing AI-powered upper-extremity rehabilitation. The company has around 30 workers as of March 2023 and reported USD 1.81 million in trailing twelve-month revenue. Bionik’s InMotion ARM and InMotion ARM/HAND robotic therapy systems use artificial intelligence and machine learning to provide therapy that responds to patient movement data in real-time, differentiating its systems from fixed-trajectory neuro-robotic competitors. The company’s AI-optimized procedures have shown up to a 25% improvement in timeframes for motor recovery over standardized programs in early clinical studies. Bionik is a tiny company with limited capital resources and is unable to support large-scale clinical trials or develop manufacturing capacity, and is dependent on strategic alliances and grant financing.

6. BrainCo (Qiangnao Technology) | Private | Hangzhou, Zhejiang, China

BrainCo is a private company based in Hangzhou that develops non-invasive brain-computer interface technology for rehabilitation, education and assistive applications. In January 2026, the firm raised CNY 2 billion (about USD 286 million), the largest BCI financing in the world outside of Neuralink, co-led by IDG Capital and Walden International, with strategic participation from Lens Technology and Omnivision Integrated Circuits Group. The funding will allow BrainCo to ramp up production of its neuro-controlled prosthetic hands and EEG-based cognitive rehabilitation devices. The product range includes smart bionic prosthetics, EEG headbands for attention training and sleep aids. The rehabilitation line is targeted to help the 1 million people with limb problems it hopes to serve in 5-10 years. BrainCo has a manufacturing advantage since it is located close to China’s electronics supply chain, which allows it to do quick prototyping and cut costs in ways that Western competitors can’t. However, the company’s 2019 classroom EEG headband trials raised data privacy and consent concerns that could hinder international expansion.

7. MindMaze Therapeutics Holding SA | SIX: MMTX | Lausanne, Switzerland

MindMaze Therapeutics (SIX: MMTX) is a Swiss digital neurotherapeutics startup developing VR-based cognitive rehabilitation and motor therapy systems for neurological illnesses. The company became public in December 2025 through a reverse merger with Relief Therapeutics, with NeuroX stockholders retaining some 90% of the combined entity. For the year ending Dec. 31, 2025, MindMaze reported revenues of CHF 0.6 million, operating expenses of CHF 11.2 million and a net loss of CHF 9.9 million. The company’s MindMotion platform provides gamified neurorehabilitation exercises for stroke, traumatic brain injury and Parkinson’s disease patients, with devices installed in clinical and residential settings globally. In March 2026, the business appointed Zach Henderson as Chief Executive Officer, who has over 30 years of expertise establishing and expanding health technology systems.

8. Neurolutions, Inc. | Private | Santa Cruz, California, USA

Neurolutions is a private medical device company headquartered in Santa Cruz, California, developing brain-computer interface technology for chronic stroke rehabilitation. The company's IpsiHand® Upper Extremity Rehabilitation System received FDA De Novo market authorization in April 2021 — the first BCI device cleared for stroke rehabilitation — and also holds FDA Breakthrough Device designation, which streamlines Medicare reimbursement pathways.

The IpsiHand system includes a wireless handpiece, non-invasive EEG headgear, and tablet-guided therapy protocol that converts brain signals from the uninjured hemisphere into actual hand movement, enabling muscle re-education in chronic stroke patients (≥6 months post-stroke). Clinical investigations showed that around 70% of the subjects had better arm and hand movement, with an average increase of 8.1 points on the Fugl-Meyer Assessment after 12 weeks. The device is covered by Medicare, VA and other commercial health plans on a case-by-case basis.

9. Nexstim Plc | NASDAQ Helsinki | Helsinki, Finland

Nexstim is a publicly traded Finnish medical technology company specializing in navigated transcranial magnetic stimulation (nTMS) systems for pre-surgical motor mapping and therapeutic neurostimulation. The company achieved 25.6% year-over-year revenue growth in 2025, with full-year revenue of EUR 11.0 million (up from EUR 8.7 million in 2024), and achieved positive operating profit for the first time. Nexstim sold approximately 35 systems in 2025, with a particularly strong H2 performance driven by therapy system demand. The company's NBS System provides navigated brain stimulation for pre-surgical motor and speech mapping, while the NBT Therapy System delivers targeted TMS for stroke rehabilitation and depression treatment. Nexstim's navigated stimulation technology — which uses 3D MRI-based neuronavigation to target stimulation coils precisely — differentiates it from non-navigated TMS competitors by ensuring reproducible, patient-specific treatment delivery. The company's updated Sinaptica partnership agreement, while reducing near-term cash payments, preserves long-term collaboration potential in the perfusion therapy market.

10. Nuvectra Corporation | Defunct (Chapter 11, Nov 2019) | Plano, Texas, USA

Nuvectra Corporation was a neurostimulation device developer that filed for Chapter 11 bankruptcy in November 2019 and subsequently ceased operations. The company's Algovita spinal cord stimulation system and Virtis sacral neuromodulation system were spin-offs from Greatbatch (now Integer Holdings), inheriting considerable engineering expertise but ultimately failing to achieve commercial scale in a market dominated by Medtronic, Abbott, Boston Scientific, and Nevro. Nuvectra's bankruptcy illustrates the capital intensity and competitive dynamics of the neuromodulation market. Despite possessing FDA-cleared products and a capable engineering team, the company could not secure sufficient market share or funding to sustain operations against competitors with deeper sales infrastructures and broader product portfolios. The company's assets were subsequently acquired by Cirtec Medical in May 2020. Nuvectra's failure serves as a cautionary signal for smaller neurorehabilitation device developers: regulatory clearance alone is insufficient without the commercial infrastructure, capital reserves, and payer relationships required to compete against established neuromodulation leaders.

M&A Activity Tracker (2021–2026)

The Neurorehabilitation Devices Market has experienced selective but strategically significant consolidation as digital health platforms, private equity, and large medtech companies acquire specialized neuro-robotic and BCI capabilities to fill capability gaps. Market Research Future tracks the following verified, named transactions directly relevant to the neurorehabilitation devices market.

Key Trend: MRFR analysis identifies two dominant M&A themes in the neurorehabilitation devices market. First, the vertical integration of BCI and digital neurotherapeutic assets into publicly listed vehicles — illustrated by MindMaze's reverse merger with Relief Therapeutics — reflects the capital-market pressure on pre-revenue neurotech companies to access public funding. Second, the separation of rehabilitation assets from diversified healthcare conglomerates into standalone, private-equity-backed entities — seen in Humana's divestiture of Kindred at Home's hospice business and Sodexo's sale of Worldwide Home Care — demonstrates that focused, pure-play rehabilitation platforms command higher strategic valuations than embedded divisions.

R&D Investment & Innovation Signals

R&D and technology investment across the Neurorehabilitation Devices Market has accelerated as operators invest in closed-loop neurostimulation, AI-driven therapy personalization, non-invasive BCI platforms, and digital therapeutics — addressing the primary operational constraints of clinical evidence generation, reimbursement code expansion, and workforce shortage that define competitive differentiation.

• Medtronic's Percept™ RC neurostimulator with BrainSense™ technology captures real-time local field potential data from implanted electrodes, enabling the first commercially available closed-loop adaptive deep brain stimulation for Parkinson's disease. This capability shifts the competitive axis from fixed-parameter stimulation to personalized, always-learning therapy systems that competitors without BrainSense™-equivalent sensing cannot match.

• Abbott Laboratories' USD 2.84 billion annual R&D investment (FY2024) funds a neuromodulation pipeline spanning next-generation DBS, SCS, and BCI research, with the company's Medical Devices segment achieving a 32.4% operating margin that provides sustained funding for long-cycle neurotechnology development unavailable to smaller, capital-constrained competitors.

• BrainCo's USD 286 million January 2026 funding round — the largest BCI financing outside Neuralink — will accelerate non-invasive BCI R&D and manufacturing scale-up in China, creating a manufacturing cost advantage that Western neurorehabilitation device companies may struggle to match in price-sensitive emerging markets.

• Neurolutions' IpsiHand System received CMS coverage on a case-by-case basis following its April 2021 FDA De Novo clearance, establishing the first reimbursement precedent for home-use BCI stroke rehabilitation — a signal that payers are beginning to recognize BCI therapy as a cost-effective alternative to extended inpatient rehabilitation.

• MindMaze's MindMotion VR platform integrates motion capture, gamified exercises, and telehealth supervision into a single digital neurotherapeutic system, positioning the company to capture the shift from hardware-based to software-based rehabilitation revenue models where recurring subscription fees replace one-time device sales.